Risk of Venous and Arterial Thromboembolic Events Associated with Anti-VEGF Agents in Advanced Non-small-cell Lung Cancer: a Meta-analysis and Systematic Review

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Jul 7

PMID 27382307

Citations 6

Authors

Dianbao Zhang

Xianfen Zhang

Chunling Zhao

Affiliations

Soon will be listed here.

Abstract

Aims: To assess the incidence and risk of arterial and venous thromboembolic events (ATEs and VTEs) associated with antivascular endothelial growth factor (VEGF) agents, including VEGF receptor-tyrosine kinase inhibitors and VEGF monoclonal antibodies, in advanced non-small-cell lung cancer (NSCLC) patients.

Methods: We performed a broad search of PubMed for relevant trials. Prospective randomized trials evaluating therapy with or without anti-VEGF agents in patients with advanced NSCLC were included for analysis. Data on VTEs and ATEs were extracted. The overall incidence, Peto odds ratio (Peto OR), and 95% confidence intervals (CIs) were pooled according to the heterogeneity of included trials.

Results: A total of 13,436 patients from 23 trials were included for analysis. Our results showed that anti-VEGF agents significantly increased the risk of developing high-grade ATEs (Peto OR: 1.44, 95% CI: 1.00-2.07, P=0.048), but not for all-grade ATEs (Peto OR: 0.94, 95% CI: 0.56-1.59, P=0.82) compared with controls. Additionally, no increased risk of all-grade and high-grade VTEs (Peto OR: 0.94, 95% CI: 0.67-1.31, P=0.71 and Peto OR: 0.95, 95% CI: 0.73-1.22, P=0.67, respectively) was observed in advanced NSCLC patients receiving anti-VEGF agents.

Conclusion: The use of anti-VEGF agents in advanced NSCLC patients significantly increased the risk of high-grade ATEs, but not for VTEs. Clinicians should be aware of the risk of severe ATEs with administration of these drugs in advanced NSCLC patients.

Citing Articles

Effect of intravitreal Bevacizumab on coagulation profile of patients with diabetic retinopathy.

Khalid I, Malik T, Tariq H, Sajid U Pak J Med Sci. 2025; 41(2):355-358.

PMID: 39926679 PMC: 11803783. DOI: 10.12669/pjms.41.2.10289.

Charpidou A, Gerotziafas G, Popat S, Araujo A, Scherpereel A, Kopp H Cancers (Basel). 2024; 16(2).

PMID: 38275891 PMC: 10814098. DOI: 10.3390/cancers16020450.

Circulating Extracellular-Vesicle-Incorporated MicroRNAs as Potential Biomarkers for Ischemic Stroke in Patients With Cancer.

Bang O, Kim E, Oh M, Yoo J, Oh G, Chung J J Stroke. 2023; 25(2):251-265.

PMID: 37106564 PMC: 10250879. DOI: 10.5853/jos.2022.02327.

Myocardial Ischemia Related to Common Cancer Therapy-Prevention Insights.

Badescu M, Badulescu O, Scripcariu D, Butnariu L, Bararu-Bojan I, Popescu D Life (Basel). 2022; 12(7).

PMID: 35888122 PMC: 9325217. DOI: 10.3390/life12071034.

Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Falanga A, Brenner B, Khorana A, Francis C Res Pract Thromb Haemost. 2022; 6(5):e12744.

PMID: 35794962 PMC: 9248072. DOI: 10.1002/rth2.12744.

References

Wang Z, Zhang J, Zhang L, Liu P, Xie Y, Zhou Q . Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. J Chemother. 2015; 28(4):328-34. DOI: 10.1179/1973947815Y.0000000053. View

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y . Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15(11):1236-44. DOI: 10.1016/S1470-2045(14)70381-X. View

Sweeting M, Sutton A, Lambert P . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004; 23(9):1351-75. DOI: 10.1002/sim.1761. View

Moher D, Pham B, Jones A, Cook D, Jadad A, Moher M . Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998; 352(9128):609-13. DOI: 10.1016/S0140-6736(98)01085-X. View

Zhu X, Wu S, Dahut W, Parikh C . Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49(2):186-93. DOI: 10.1053/j.ajkd.2006.11.039. View

Hapani S, Sher A, Chu D, Wu S . Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010; 79(1-2):27-38. DOI: 10.1159/000314980. View

Ferrara N . Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2003; 29(6 Suppl 16):10-4. DOI: 10.1053/sonc.2002.37264. View

Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Wiedemann J, Sirzen F . Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011; 29(13):1757-64. DOI: 10.1200/JCO.2010.32.3220. View

Qi W, Shen Z, Tang L, Yao Y . Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol. 2014; 92(2):71-82. DOI: 10.1016/j.critrevonc.2014.04.004. View

10.

Paz-Ares L, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J . Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012; 30(25):3084-92. DOI: 10.1200/JCO.2011.39.7646. View

11.

Choueiri T, Mayer E, Je Y, Rosenberg J, Nguyen P, Azzi G . Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011; 29(6):632-8. DOI: 10.1200/JCO.2010.31.9129. View

12.

Zintzaras E, Ioannidis J . Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2004; 28(2):123-37. DOI: 10.1002/gepi.20048. View

13.

Khorana A, Francis C, Culakova E, Kuderer N, Lyman G . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3):632-4. DOI: 10.1111/j.1538-7836.2007.02374.x. View

14.

Reck M, Kaiser R, Mellemgaard A, Douillard J, Orlov S, Krzakowski M . Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2):143-55. DOI: 10.1016/S1470-2045(13)70586-2. View

15.

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

17.

Schutz F, Je Y, Azzi G, Nguyen P, Choueiri T . Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2010; 22(6):1404-1412. DOI: 10.1093/annonc/mdq587. View

18.

Ay C, Dunkler D, Marosi C, Chiriac A, Vormittag R, Simanek R . Prediction of venous thromboembolism in cancer patients. Blood. 2010; 116(24):5377-82. DOI: 10.1182/blood-2010-02-270116. View

19.

Qi W, Shen Z, Tang L, Yao Y . Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol. 2014; 78(4):748-62. PMC: 4239969. DOI: 10.1111/bcp.12387. View

20.

Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto A, de Marinis F . Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. J Thorac Oncol. 2014; 9(5):733-7. DOI: 10.1097/JTO.0000000000000120. View